查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018930

生物影像市场：按产品、技术、模式、应用和最终用户划分－2026-2032年全球市场预测

Bio-imaging Market by Product, Technology, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物成像市场价值将达到 73.8 亿美元，到 2026 年将成长到 81.3 亿美元，到 2032 年将达到 149 亿美元，复合年增长率为 10.55%。

主要市场统计数据
基准年 2025 73.8亿美元
预计年份：2026年 81.3亿美元
预测年份 2032 149亿美元
复合年增长率 (%) 10.55%

清晰权威地阐述了整合成像技术、分析和临床工作流程如何重塑诊断准确性和调查路径。

生物影像领域正经历着翻天覆地的变化，硬体、软体和临床整合的同步进步推动着这项变革。影像方式曾经各自独立地应用于诊断和手术，如今正融合为混合工作流程，优先考虑诊断准确性、工作流程效率和资料互通性。临床医生和研究人员越来越重视影像衍生分析、纵向资料撷取和可重复的影像方案，以支持个人化医疗和转化研究。

人工智慧整合、模态混合、基于云端的协作和流程去中心化如何共同重新定义生物成像领域的临床工作流程和商业化模式。

影像产业正经历一场变革性的转变，不再局限于产品效能的渐进式改进，而是从系统层面改变诊断影像的执行、分析和报销方式。人工智慧 (AI) 和机器学习已从概念验证(PoC) 模型发展成为嵌入式工具，能够增强放射科医生的工作流程，自动化常规影像处理任务，并提取临床可用的生物标记。因此，人们的关注点集中在模型检验、监管核准流程以及如何将 AI 输出整合到临床决策支援系统中。

评估 2025 年贸易政策变化对影像相关人员供应链韧性、区域製造策略和采购决策的策略影响。

2025年的关税状况​​为全球医疗影像硬体、组件和耗材的供应链和采购决策带来了新的复杂性。进口关税的增加和贸易政策的调整可能会推高依赖海外组件的系统总成本，迫使製造商重新评估其供应商所在地和製造地。为此，许多公司正在加快供应商多元化进程，并选择替代组件来源，以维持生产的连续性并确保获利能力。

将特定模式的创新、产品组合、应用需求和最终用户采购行为与商业性机会连结起来的策略性细分洞察。

细分市场分析揭示了技术、产品、模式、应用和最终用户等维度上创新与商业性机会的交汇点。从技术层面来看，磁振造影(MRI) 和 X 光成像等成熟模式仍是诊断的核心，而内视镜、核子医学影像、手术显微镜和超音波技术则透过解析度、便携性和整合性的提升，不断拓展其临床应用范围。这种技术多样性要求供应商开发针对特定模式的临床工作流程和报销趋势的价值提案。

美洲、欧洲、中东、非洲和亚太地区的区域战略趋势和独特的实施模式，决定了针对每个地区量身定制的商业化和监管方法。

区域趋势正显着影响着美洲、欧洲、中东和非洲以及亚太地区的采用模式、监管路径和商业性策略。在美洲，由于医院网路整合以及对门诊和日间护理设施投资的增加，医疗保健系统对先进诊断能力和软体主导的效率提升有着强劲的需求。这种环境推动了能够展现临床疗效并降低营运成本的整合解决方案的发展，而报销趋势和监管考量则影响这些解决方案的采用速度。

本报告揭示了成熟企业、创新者和软体专家如何透过伙伴关係、併购和证据生成进行协作，从而在生物成像领域建立竞争优势，并重点介绍了竞争和合作的商业趋势。

生物成像领域的竞争格局由成熟的跨国公司、敏捷的医疗设备创新者和专业软体供应商组成。成熟的製造商拥有规模优势、庞大的基本客群和丰富的监管合规经验，这些优势支撑着高价设备销售和长期服务合约。同时，中小企业和Start-Ups正在迅速推出影像分析、云端原生资料管理和照护现场设备等方面的颠覆性功能，并透过伙伴关係、授权协议和有针对性的收购来加速自身能力建设。

为领导者提供切实可行的策略指导，以加强供应链韧性，加速成熟人工智慧的采用，并使模组化商业化适应当地市场实际情况。

产业领导者应推动一系列合作倡议，将技术潜力转化为永续的商业性优势。首先，实现供应链多元化，并对跨区域的製造合作伙伴进行认证，以降低贸易政策波动和关键零件短缺的风险。其次，优先发展模组化产品设计和服务，以实现更快的升级、更便利的维护，并提供多样化的资金筹措模式，以满足门诊诊所、诊断中心和医院的采购需求。第三，加快对检验的人工智慧和分析技术的投资，重点关注可解释性、临床检验和合规性，以增强临床医生的信心并获得支付方的认可。

严谨的多方法研究设计，结合一手访谈、第二手资料整合和反覆检验，确保为相关人员。

本研究整合了定性和定量相结合的多方面研究方法。初步调查包括对临床负责人、采购负责人、技术主管和监管专家进行结构化访谈和情境研讨会，以识别挑战、应用驱动因素和商业优先事项。第二次调查包括对同行评审文献、监管申报文件、临床指南和技术白皮书进行系统性回顾，以了解技术趋势和证据要求。

随着生物影像技术改变临床护理和研究，综合技术、检验的证据和在地化策略简洁地整合了决定谁能获得价值的机制。

总而言之，生物成像正处于转折点，技术进步必须与切实可行的商业化策略相契合。先进的影像模式、人工智慧驱动分析以及云端原生资料架构的融合，在释放新的临床能力的同时，也提高了人们对证据、互通性和资料管治的期望。监管的复杂性和地缘政治贸易动态为战略考量增添了新的层面，迫使各组织调整供应链、加速临床检验并完善经营模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物影像市场：依产品划分

  • 影像系统
  • 装置
    • CT扫描仪
    • 核磁共振造影系统
    • 超音波设备
  • 试剂
  • 软体
    • 资料管理软体
    • 影像分析软体

第九章：生物影像市场：依技术划分

  • 内视镜
  • 磁振造影
  • 核子医学扫描术诊断
  • 手术显微镜
  • 超音波
  • X光影像诊断

第十章：生物影像市场：依影像方式划分

  • 二维成像
  • 三维成像

第十一章：生物造影市场：按应用领域划分

  • 临床诊断
  • 药物发现
  • 研究
  • 治疗

第十二章 生物影像市场：依最终用户划分

  • 门诊手术中心
  • 诊断影像中心
  • 医院和诊所

第十三章：生物影像市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物影像市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：生物影像市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物影像市场

第十七章：中国生物成像市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • BaySpec, Inc.
  • Bracco SpA
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Digirad Corporation
  • Esaote SpA
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hitachi Medical Corporation
  • HT BioImaging Ltd
  • iThera Medical GmbH
  • Kitware, Inc.
  • Koninklijke Philips NV
  • Lantheus Medical Imaging, Inc.
  • M Squared Lasers Ltd.
  • MARS Bioimaging Limited
  • Medtronic PLC
  • MobileODT Ltd by Liger Medical LLC
  • Perspectum Ltd.
  • Quibim, SL
  • RadNet, Inc.
  • Rivanna Medical, Inc.
  • Samsung Medison Co., Ltd.
  • Siemens Healthineers
Product Code: MRR-710B1F0AC3D1

The Bio-imaging Market was valued at USD 7.38 billion in 2025 and is projected to grow to USD 8.13 billion in 2026, with a CAGR of 10.55%, reaching USD 14.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.38 billion
Estimated Year [2026] USD 8.13 billion
Forecast Year [2032] USD 14.90 billion
CAGR (%) 10.55%

A clear and authoritative framing of how convergent imaging technologies, analytics, and clinical workflows are reshaping diagnostic precision and research pathways

The bio-imaging landscape is undergoing a profound evolution driven by parallel advances in hardware, software, and clinical integration. Imaging modalities that were once siloed within diagnostic or surgical contexts are converging into hybrid workflows that prioritize diagnostic precision, workflow efficiency, and data interoperability. Clinicians and researchers alike are placing greater emphasis on image-derived analytics, longitudinal data capture, and reproducible imaging protocols to support personalized care and translational research.

Against this backdrop, investments in image analysis software, cloud-native data management, and device interoperability are reshaping procurement priorities across end users. These shifts are not merely technological; they reflect changing clinical pathways that integrate imaging more tightly into therapeutic decision-making and drug development pipelines. As a result, manufacturers and solution providers must align innovation strategies with evolving clinician needs, regulatory expectations, and payer-driven demands for demonstrable clinical value. This introduction frames the executive summary that follows, setting the stage for detailed discussion of market dynamics, policy impacts, segmentation nuances, regional variations, and recommended actions for leaders navigating this fast-evolving sector.

How AI integration, modality hybridization, cloud-enabled collaboration, and procedural decentralization are jointly redefining clinical workflows and commercialization models in bio-imaging

The industry is experiencing transformative shifts that extend beyond incremental product improvements to systemic changes in how imaging is performed, analyzed, and reimbursed. Artificial intelligence and machine learning have matured from proof-of-concept models into embedded tools that augment radiologist workflows, automate routine image processing tasks, and surface clinically actionable biomarkers. Consequently, attention has turned to model validation, regulatory approval pathways, and strategies to integrate AI outputs into clinical decision support systems.

Simultaneously, hybridization of modalities-where endoscopy is combined with high-resolution imaging, or ultrasound is augmented by contrast agents and AI interpretation-has expanded clinical utility across specialties. Cloud-based data management and secure federated learning approaches are enabling multi-institutional collaboration, while edge computing is facilitating near-patient inference for point-of-care diagnostics. Device miniaturization and advances in surgical microscopy are shifting procedures from inpatient to ambulatory and outpatient settings, altering purchasing cycles and capital planning. Collectively, these shifts demand that stakeholders adopt flexible commercialization models, invest in regulatory and evidence generation capabilities, and form partnerships that bridge hardware, software, and clinical services.

Assessing the strategic implications of 2025 trade policy changes on supply chain resilience, regional manufacturing strategies, and procurement decision-making across imaging stakeholders

The tariff landscape of 2025 has introduced new complexities into global supply chains and procurement decisions for imaging hardware, components, and consumables. Increased import duties and trade policy adjustments have the potential to raise landed costs for systems that rely on internationally sourced components, intensifying pressure on manufacturers to reassess supplier footprints and manufacturing locations. In response, many firms are accelerating supplier diversification and qualifying alternate component sources to sustain production continuity and preserve margin integrity.

Beyond direct cost implications, tariffs influence strategic choices about localization, inventory strategies, and pricing transparency with customers. Some vendors are evaluating regional assembly or final-stage manufacturing to mitigate tariff exposure while others are negotiating long-term supplier agreements to secure priority access to constrained components. Additionally, regulatory compliance and customs classification have become more prominent as companies seek to optimize tariff treatments and leverage trade facilitation mechanisms. The aggregate effect is a recalibration of procurement timelines, capital allocation, and partnership strategies as organizations adapt to a more fragmented and policy-sensitive trade environment.

Strategic segmentation insights that connect modality-specific innovation, product composition, application needs, and end-user procurement behavior to commercial opportunity

Segmentation analysis illuminates where innovation and commercial opportunity intersect across technology, product, modality, application, and end-user dimensions. When considering technology, mature modalities such as magnetic resonance imaging and X-ray imaging continue to be core diagnostic pillars, while endoscopy, nuclear imaging, surgical microscopy, and ultrasound are expanding their clinical reach through enhancements in resolution, portability, and integration. This technological diversity requires vendors to tailor value propositions that align with modality-specific clinical workflows and reimbursement dynamics.

Product segmentation reveals that imaging systems and instruments remain central to capital investment decisions, yet reagents and software are increasingly important as recurring revenue drivers and enablers of differentiated clinical outcomes. Within instruments, CT scanners, MRI machines, and ultrasound devices have distinct procurement cycles and service models that influence total cost of ownership conversations. Software divides broadly into data management platforms that address interoperability and security, and image analysis tools that deliver analytic insights; both categories play a growing role in vendor differentiation. Modality distinctions between 2D and 3D imaging underscore divergent requirements for image acquisition, storage, and interpretation, particularly in applications spanning clinical diagnostics, drug discovery, research, and therapeutics. End users such as ambulatory surgical centers, diagnostic imaging centers, and hospitals and clinics each prioritize different combinations of throughput, capital expense, and integration with electronic health records, shaping purchase criteria and post-sale service expectations. By interpreting segmentation through the lens of clinical workflows and purchasing behavior, organizations can better align product road maps and commercial models to specific demand drivers.

Regional strategic dynamics and differentiated adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform tailored commercialization and regulatory approaches

Regional dynamics materially influence adoption patterns, regulatory pathways, and commercial approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems exhibit a strong appetite for advanced diagnostic capabilities and software-driven efficiency gains, supported by consolidated hospital networks and growing investment in outpatient and ambulatory care sites. This environment favors integrated solutions that demonstrate clinical impact and operational savings, while reimbursement dynamics and regulatory considerations guide the pace of adoption.

Europe Middle East & Africa presents a heterogeneous landscape where regulatory stringency, national health priorities, and infrastructure variability shape market entry strategies. Some markets emphasize centralized, high-quality imaging centers and national screening programs, prompting demand for scalable, interoperable solutions. Other markets are investing in capacity expansion and modernization, creating opportunities for modular systems and remote service offerings. Asia-Pacific is characterized by rapid expansion of diagnostic infrastructure, investments in local manufacturing, and strong interest in cost-effective, high-throughput technologies. Private healthcare growth and public initiatives to improve access to diagnostics are driving demand for both high-end modalities and portable point-of-care devices. Across regions, localization of service networks, compliance with regional regulatory frameworks, and culturally informed clinical validation are essential for successful commercialization. Understanding these regional distinctions enables targeted resource allocation and partnership selection to accelerate market penetration.

Competitive and collaborative company trends that reveal how incumbents, innovators, and software specialists are aligning through partnerships, M&A, and evidence generation to win in bio-imaging

Competitive dynamics in bio-imaging are shaped by a mix of legacy multinationals, nimble device innovators, and specialist software vendors. Legacy manufacturers retain strengths in scale, installed base service networks, and regulatory experience, which support large capital sales and long-term service agreements. At the same time, smaller firms and startups are rapidly introducing disruptive capabilities in image analysis, cloud-native data management, and point-of-care devices, prompting partnerships, licensing agreements, and targeted acquisitions to accelerate capability build-out.

Strategic collaborations between device OEMs and software companies are becoming more commonplace as hardware vendors seek to bundle analytic and data services that demonstrate measurable clinical value. Partnerships with academic medical centers and clinical research organizations are also essential for evidence generation and regulatory submissions. Moreover, companies that invest in robust post-market surveillance, cyber-security safeguards, and interoperability standards position themselves favorably with health systems that require secure, auditable data flows. The competitive landscape rewards firms that can integrate clinical validation, regulatory strategy, and go-to-market agility into a cohesive commercialization plan.

Actionable strategic guidance for leaders to enhance supply chain resilience, accelerate validated AI adoption, and align modular commercialization with regional market realities

Industry leaders should pursue a set of coordinated actions to translate technological promise into sustainable commercial advantage. First, diversify supply chains and qualify multi-regional manufacturing partners to reduce exposure to trade policy volatility and critical component shortages. Second, prioritize modular product design and services that enable faster upgrades, easier maintenance, and varied financing models adapted to ambulatory, diagnostic center, and hospital procurement preferences. Third, accelerate investment in validated AI and analytics, focusing on explainability, clinical validation, and regulatory alignment to build clinician trust and payer acceptance.

In parallel, strengthen strategic partnerships with software vendors, academic centers, and specialty service providers to co-develop evidence that links imaging outputs to improved patient outcomes. Implement robust data governance, cybersecurity, and interoperability frameworks to facilitate multi-institutional collaboration and secure cloud deployments. Finally, align commercialization plans with regional nuances by tailoring product configurations, service models, and reimbursement strategies to local market realities. These actions collectively reduce execution risk, increase adoption velocity, and create defensible differentiation in a competitive landscape.

Rigorous multi-method research design combining primary interviews, secondary evidence synthesis, and iterative validation to ensure robust, actionable insights for stakeholders

The study synthesizes insights from a multi-method research approach combining qualitative and quantitative techniques. Primary research consisted of structured interviews and scenario workshops with clinical leaders, procurement officers, technology executives, and regulatory specialists to surface pain points, adoption drivers, and commercial priorities. Secondary research involved a systematic review of peer-reviewed literature, regulatory filings, clinical guidelines, and technical whitepapers to contextualize technological trends and evidence requirements.

Data triangulation was used to reconcile insights across sources, while thematic analysis highlighted recurring adoption barriers and success factors. Validation exercises with external experts and iterative feedback loops ensured that conclusions reflect practical realities encountered by field stakeholders. Methodological rigor was maintained through transparent documentation of data sources, interview frameworks, and assumption checks, enabling reproducibility and confidence in the study's recommendations. Ethical considerations and confidentiality protocols were observed during primary engagements to protect proprietary information shared by participants.

Concise synthesis of how integrated technology, validated evidence, and regionally informed strategy will determine who captures value as bio-imaging transforms clinical care and research

In summary, bio-imaging stands at an inflection point where technological sophistication must be matched by pragmatic commercialization strategies. The convergence of advanced modalities, AI-enabled analytics, and cloud-native data architectures is unlocking new clinical capabilities while simultaneously raising expectations for evidence, interoperability, and data stewardship. Regulatory complexity and geopolitical trade dynamics add layers of strategic consideration, compelling organizations to adapt supply chains, accelerate clinical validation, and refine commercial models.

Decision-makers who act decisively to integrate validated software, modular hardware, and regionally attuned service models will be best positioned to capture value. Equally important is the ability to demonstrate measurable clinical and economic impact, which increasingly governs adoption and reimbursement. By aligning innovation road maps with clinician workflows, payer priorities, and regional regulatory contexts, stakeholders can convert technical advances into scalable clinical solutions that improve outcomes and operational efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bio-imaging Market, by Product

  • 8.1. Imaging Systems
  • 8.2. Instruments
    • 8.2.1. CT Scanners
    • 8.2.2. MRI Machines
    • 8.2.3. Ultrasound Devices
  • 8.3. Reagents
  • 8.4. Software
    • 8.4.1. Data Management Software
    • 8.4.2. Image Analysis Software

9. Bio-imaging Market, by Technology

  • 9.1. Endoscopy
  • 9.2. Magnetic Resonance Imaging
  • 9.3. Nuclear Imaging
  • 9.4. Surgical Microscopy
  • 9.5. Ultrasound
  • 9.6. X-ray Imaging

10. Bio-imaging Market, by Modality

  • 10.1. 2D Imaging
  • 10.2. 3D Imaging

11. Bio-imaging Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery
  • 11.3. Research
  • 11.4. Therapeutics

12. Bio-imaging Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Imaging Centers
  • 12.3. Hospitals & Clinics

13. Bio-imaging Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bio-imaging Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bio-imaging Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bio-imaging Market

17. China Bio-imaging Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. BaySpec, Inc.
  • 18.6. Bracco S.p.A.
  • 18.7. Bruker Corporation
  • 18.8. Canon Medical Systems Corporation
  • 18.9. Digirad Corporation
  • 18.10. Esaote S.p.A
  • 18.11. Fujifilm Holdings Corporation
  • 18.12. GE HealthCare Technologies, Inc.
  • 18.13. Hitachi Medical Corporation
  • 18.14. HT BioImaging Ltd
  • 18.15. iThera Medical GmbH
  • 18.16. Kitware, Inc.
  • 18.17. Koninklijke Philips N.V.
  • 18.18. Lantheus Medical Imaging, Inc.
  • 18.19. M Squared Lasers Ltd.
  • 18.20. MARS Bioimaging Limited
  • 18.21. Medtronic PLC
  • 18.22. MobileODT Ltd by Liger Medical LLC
  • 18.23. Perspectum Ltd.
  • 18.24. Quibim, S.L.
  • 18.25. RadNet, Inc.
  • 18.26. Rivanna Medical, Inc.
  • 18.27. Samsung Medison Co., Ltd.
  • 18.28. Siemens Healthineers

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIO-IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIO-IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIO-IMAGING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIO-IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIO-IMAGING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIO-IMAGING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIO-IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIO-IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIO-IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIO-IMAGING MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIO-IMAGING MARKET SIZE, BY CT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIO-IMAGING MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIO-IMAGING MARKET SIZE, BY MRI MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIO-IMAGING MARKET SIZE, BY MRI MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIO-IMAGING MARKET SIZE, BY MRI MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIO-IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIO-IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIO-IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIO-IMAGING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIO-IMAGING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIO-IMAGING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIO-IMAGING MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIO-IMAGING MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIO-IMAGING MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIO-IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIO-IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIO-IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIO-IMAGING MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIO-IMAGING MARKET SIZE, BY NUCLEAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIO-IMAGING MARKET SIZE, BY NUCLEAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIO-IMAGING MARKET SIZE, BY SURGICAL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIO-IMAGING MARKET SIZE, BY SURGICAL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIO-IMAGING MARKET SIZE, BY SURGICAL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIO-IMAGING MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIO-IMAGING MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIO-IMAGING MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIO-IMAGING MARKET SIZE, BY 2D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIO-IMAGING MARKET SIZE, BY 2D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIO-IMAGING MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIO-IMAGING MARKET SIZE, BY 3D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIO-IMAGING MARKET SIZE, BY 3D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIO-IMAGING MARKET SIZE, BY 3D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIO-IMAGING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIO-IMAGING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIO-IMAGING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIO-IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIO-IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIO-IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIO-IMAGING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIO-IMAGING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIO-IMAGING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIO-IMAGING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIO-IMAGING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIO-IMAGING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIO-IMAGING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIO-IMAGING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIO-IMAGING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIO-IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIO-IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIO-IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIO-IMAGING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIO-IMAGING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIO-IMAGING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIO-IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BIO-IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIO-IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)